Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Ranbaxy Applies For New Plant To Make Drugs For U.S.

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories has applied to the U.S. FDA for clearance to build a plant in Punjab to produce drugs for the U.S. market. The plant would be the company's fourth allowed to produce U.S.-bound pharmaceuticals. The other three are being eyed carefully by the same agency for allegedly producing contaminated drugs exported to the United States. Ranbaxy expects U.S. approval for the plant in Mohali by the end of next year. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts